Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Wins Third US Patent for Fungicide Technology

NEW YORK, May 15 - Paradigm Genetics has been issued a patent in the United States for "Methods and Materials for the Rapid and High Volume Production of a Gene Knock-Out Library in an Organism."

 

The patent, No. 6,562,624, covers Paradigm's Transposon-Arrayed Gene Knock-Out technology, which according to the company provides methods "for the rapid and systematic mutation of pathogenic fungi." These methods are designed to enable researchers to identify antifungal and fungicide targets, as well as biosynthetic and degradation pathways, Paradigm said.

 

To date, Paradigm has won two Notices of Allowance from the US Patent and Trademark Office for fungicide target patent applications. They are: "Methods for the Identification of Inhibitors of 5-Aminolevulinate Synthase as Antibiotics" and "Methods for the Identification of Inhibitors of Threonine Synthase as Antibiotics."

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.